OncoMyx Therapeutics Revenue and Competitors

Phoenix, AZ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • OncoMyx Therapeutics's estimated annual revenue is currently $1.2M per year.(i)
  • OncoMyx Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • OncoMyx Therapeutics has 6 Employees.(i)
  • OncoMyx Therapeutics grew their employee count by -50% last year.

OncoMyx Therapeutics's People

NameTitleEmail/Phone
1
VP OperationsReveal Email/Phone
2
VP PeopleReveal Email/Phone
3
ControllerReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Scientist, Oncolytic VirotherapyReveal Email/Phone
6
CMC AdvisorReveal Email/Phone
7
Finance AdvisorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.3M1118%N/AN/A
#2
$17.7M88-19%N/AN/A
#3
$6.6M33-8%N/AN/A
#4
$29.1M14548%N/AN/A
#5
$1.2M6-50%N/AN/A
#6
$2.2M1110%N/AN/A
#7
$4.8M24-17%N/AN/A
#8
$34.8M1735%N/AN/A
#9
$46.2M2305%N/AN/A
#10
$3.2M16-11%N/AN/A
Add Company

What Is OncoMyx Therapeutics?

OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

keywords:N/A

N/A

Total Funding

6

Number of Employees

$1.2M

Revenue (est)

-50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OncoMyx Therapeutics News

2022-04-06 - UArizona Health Sciences selects downtown Phoenix for research ...

"Companies like OncoMyx Therapeutics are developing innovative treatments, and our health-care leaders are working to address current needs...

2022-04-06 - OncoMyx Presents New Data at AACR 2022 Demonstrating Multi ...

OncoMyx Therapeutics is advancing multi-armed, systemic immunotherapies with the potential to be broadly effective in treating solid tumors and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M6N/AN/A
#2
$0.8M6-45%N/A
#3
$0.5M60%N/A
#4
$0.7M6-67%N/A
#5
$0.6M6N/AN/A